课题基金 / 基金详情

A New Platform for Detailed Analysis of High Value Proteins

A New Platform for Detailed Analysis of High Value Proteins
详细分析高价值蛋白质的新平台
批准号:
BB/W020270/1
负责人:
Karl Burgess
金额:
$67.06万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
已结题
起止时间:
2023 至 --

项目摘要

项目成果

Karl Burgess的其他基金

相似基金

相关文献

中文摘要
翻译
我们需要一台安捷伦6560C离子迁移质谱仪来加速我们的工程生物学平台。全球工业正在转向使用生物基和可再生资源生产化学品,如塑料、洗涤剂、染料和药品。工程生物学是对细胞进行修饰的术语,这些细胞可以成为我们的“未来工厂”。它允许研究人员选择或修改细胞执行的普通化学过程,并为它们提供新的化学过程。以哺乳动物细胞为例,例如典型的中国仓鼠卵巢细胞,合成生物学家可以生产出非常有价值的蛋白质药物,如抗癌剂、疫苗和罕见疾病的治疗方法。虽然我们在ue的专家团队现在有强大的自动化系统来修改哺乳动物细胞,但我们很难测试它们,看看它们的工作效果如何,产品有多好(和安全)。目前对产品质量的评估是通过简单地测量产品的产量来进行的,并不能完全确定这些蛋白质的结构或共同的修饰,这些结构或修饰可能对安全性和有效性负责。全面的产品质量评估必须通过多种复杂的结构和化学方法在多个设施中完成。这意味着我们不能优化工程生物学平台,以及我们应该能够在工业和现代学术研究所需的快速周转时间内。Agilent 6560C是一种可以表征高价值蛋白质产品质量的仪器。有了这个系统,我们就可以“闭环”工程生物学,并通过快速测试,改进我们的工程细胞,以制造更安全、更好的产品。通过将这种能力添加到爱丁堡组学和爱丁堡大学的支持设施组合中,我们将为世界领先的新药研究人员提供技术,通过早期基因工程(通过爱丁堡基因组铸造厂),从早期新药生产(通过爱丁堡蛋白质生产设施)到药物质量测试(通过这种新仪器)来实现新药的想法。生产这种高度精炼的早期药物可以加速临床试验和医疗用途的吸收。
英文摘要
We request an Agilent 6560C ion mobility mass spectrometer to accelerate our engineering biology platform.Industry globally is moving over to the use of bio-based and renewable sources for chemicals, such as plastics, detergents, dyes and medicines. Engineering biology is the term given to modifications of cells that can be our 'factories of the future'. It allows researchers to select or modify the ordinary chemical processes that the cells perform and provide them with new ones. In the case of mammalian cells such as the archetypical Chinese Hamster Ovary cells, synthetic biologists can produce extremely valuable protein medicines such as anti-cancer agents, vaccines and treatments for rare diseases.While our expert teams at UoE now have powerful automated systems for modifying mammalian cells, we struggle to test them to see how well they work and how good (and safe) the products are. Currently assessment of product quality is performed by simply measuring the yield of the products, and does not fully determine the structures or the modifications common to these proteins that can be responsible for safety and efficacy. Full product quality assessment must be done by multiple complex structural and chemical methods housed in multiple facilities. This means that we cannot optimise the engineering biology platform as well as we should be able to within the rapid turnaround times required by industry and modern academic research.The Agilent 6560C is an instrument that can characterise the product quality of high value proteins. With this system, we can 'close the loop' of engineering biology, and by using rapid testing, refine our engineered cells to make safer and better products. By adding this capability to EdinOmics and the portfolio of support facilities at the University of Edinburgh, we will provide world leading researchers into new medicines with the technology to take an idea for a new drug through early stage genetic engineering (via the Edinburgh Genome Foundry), through early stage production of a new medicine (via the Edinburgh Protein Production Facility) to testing of that medicine for quality (via this new instrument). Production of such highly polished early stage medicines can accelerate their uptake for clinical trials and hence medical use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EPSRC-SFI: Cutting Edge Analytical Solutions for Smart, Integrated, Efficient Biopharmaceutical Production
  • 批准号:
    EP/V041185/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $56.45万
  • 财政年份:
    2022
  • 负责人:
    Karl Burgess
  • 依托单位:
国内基金
海外基金
Data-driven Recommendation System Construction of an Online Medical Platform Based on the Fusion of Information